Alluvi, formerly BI 4744, represents a notable advance in obesity care. This dual agonist targeting both GLP-1 and GIP sites demonstrates impressive efficacy in research studies, potentially exceeding existing GLP-1 https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/